Nuvalent (NUVL) Liabilities and Shareholders Equity (2020 - 2026)

Nuvalent (NUVL) posted Liabilities and Shareholders Equity of $1.3 billion for Q1 2026, down 5.77% on a QoQ basis from $1.4 billion in Q4 2025, and up 20.38% year-over-year from $1.1 billion in Q1 2025.

Nuvalent (NUVL) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Nuvalent's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 20.38% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 15.87% YoY) and the FY2025 annual result came in at $1.4 billion, up 23.73% from the prior year.
  • Liabilities and Shareholders Equity was $1.3 billion for Q1 2026 at Nuvalent, down from $1.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2025 and bottomed at $249.6 million in Q3 2022.
  • A 5-year average of $759.8 million and a median of $708.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 18.97% — and 2024, when it jumped 179.68%.
  • Nuvalent's Liabilities and Shareholders Equity stood at $482.5 million in 2022, then jumped by 51.8% to $732.4 million in 2023, then surged by 55.9% to $1.1 billion in 2024, then climbed by 23.73% to $1.4 billion in 2025, then dropped by 5.77% to $1.3 billion in 2026.
  • Business Quant data shows NUVL's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $979.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Nuvalent 9.75 Bn 9.75 Bn - 1.33 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.33 Bn
Dec 31, 2025 1.41 Bn
Sep 30, 2025 979.91 Mn
Jun 30, 2025 1.04 Bn
Mar 31, 2025 1.11 Bn
Dec 31, 2024 1.14 Bn
Sep 30, 2024 1.19 Bn
Jun 30, 2024 675.23 Mn
Mar 31, 2024 708.47 Mn
Dec 31, 2023 732.38 Mn
Sep 30, 2023 425.08 Mn
Jun 30, 2023 441.95 Mn
Mar 31, 2023 460.99 Mn
Dec 31, 2022 482.46 Mn
Sep 30, 2022 249.56 Mn
Jun 30, 2022 263.02 Mn
Mar 31, 2022 277.04 Mn
Dec 31, 2021 293.82 Mn
Sep 30, 2021 307.97 Mn
Jun 30, 2021 143.50 Mn